[Federal Register Volume 59, Number 25 (Monday, February 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-2652]


[[Page Unknown]]

[Federal Register: February 7, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Consensus Development Conference on Effects of Corticosteroids 
for Fetal Maturation on Perinatal Outcomes

    Notice is hereby given of the NIH Consensus Development Conference 
on ``Effects of Corticosteroids for Fetal Maturation on Perinatal 
Outcomes,'' which will be held February 28-March 2, 1994, in the Masur 
Auditorium of the National Institutes of Health, 9000 Rockville Pike, 
Bethesda, Maryland 20892. This conference is sponsored by the National 
Institute of Child Health and Human Development and the NIH Office of 
Medical Applications of Research. The conference is cosponsored by the 
National Heart, Lung, and Blood Institute and the National Institute of 
Nursing Research. The conference begins at 8:30 a.m. on February 28, 8 
a.m. on March 1, and 9 a.m. on March 2. The meeting is open to the 
public at no charge.
    One of a series of NIH Consensus Development Conferences, this 
conference will evaluate the data available related to antenatal 
corticosteroid treatment of pregnant women delivering prematurely. The 
conditions and purposes of this treatment will be reviewed, as well as 
its short-term and long-term benefits and adverse effects. In addition, 
the economic consequences of this treatment will be considered.
    After 1\1/2\ days of presentations and discussion by the audience, 
an independent non-Federal consensus panel will weigh the scientific 
evidence and write a draft consensus statement in response to the 
following key questions:
     For what conditions and purposes are antenatal 
corticosteroids used, and what is the scientific basis for that use?
     What are the short-term and long-term benefits of 
antenatal corticosteroid treatment?
     What are the short-term and long-term adverse effects for 
the infant and mother?
     What are the economic consequences of this treatment?
     What is the influence of type of corticosteroid, dosage, 
timing and circumstances of administration, and associated therapy on 
treatment outcome?
     What are the recommendations for use of antenatal 
corticosteroids?
     What research is needed to guide clinical care?
    On the final day of the meeting, the consensus panel chairman will 
read the draft statement to the conference audience and invite comments 
and questions.
    Advance information on the conference program and conference 
registration materials may be obtained from: Debra Steward, Technical 
Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland 
20852, phone (301) 770-3153.
    A draft report will be prepared before the conference by the 
consensus panel, providing preliminary information on the issues 
described above. Advance copies of this report will be available to the 
public by January 15, 1994. Interested persons or organizations may 
obtain a copy of this draft report from: Debra Steward, Technical 
Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland 
20852, phone (301) 770-3153.
    Those individuals wishing to make comments on the draft report may 
submit their comments in writing by February 14, 1994, to Mr. Jerry 
Elliott, Office of Medical Applications of Research, National 
Institutes of Health, Federal Building, Room 618, Bethesda, Maryland 
20892. Individuals may also present their comments during discussion 
periods at the conference. Written comments and discussion at the 
conference will be used to prepare the final panel report, which will 
be available approximately October 1, 1994. Statements received after 
the meeting cannot be considered by the panel in preparing their final 
report.
    On the second day of the conference, time has been allocated for 5-
10 minute formal oral presentations by concerned individuals or 
organizations. Those individuals or groups wishing to send a 
representative to contribute during this session must contact Mr. Jerry 
Elliott by 5 p.m. EST, February 14, 1994, at: Office of Medical 
Applications of Research, National Institutes of Health, Federal 
Building, room 618, Bethesda, Maryland 20892, phone (301) 496-1144.
    The final consensus statement, a document separate from the panel 
report, will be submitted for publication in professional journals and 
other publications. The final consensus statement will be available 
approximately April 1, 1994. Requests for the final consensus statement 
should be addressed to the NIH Consensus Program Information Service, 
P.O. Box 2577, Kensington, Maryland 20891, phone 1-800-NIH-OMAR (1-800-
644-6627).

    Dated: January 28, 1994.
Harold Varmus,
Director, NIH.
[FR Doc. 94-2652 Filed 2-4-94; 8:45 am]
BILLING CODE 4140-01-M